243 related articles for article (PubMed ID: 30632837)
21. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy.
Klanova M; Oestergaard MZ; Trněný M; Hiddemann W; Marcus R; Sehn LH; Vitolo U; Bazeos A; Goede V; Zeuner H; Knapp A; Sahin D; Spielewoy N; Bolen CR; Cardona A; Klein C; Venstrom JM; Nielsen T; Fingerle-Rowson G
Clin Cancer Res; 2019 Aug; 25(15):4634-4643. PubMed ID: 31053601
[TBL] [Abstract][Full Text] [Related]
22. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
Pouyiourou M; Meyer A; Stroux A; Viardot A; La Rosée P; Maschmeyer G; Kämpfe D; Kahl C; Vucinic V; Monecke A; Hirt C; Weber T; Meissner J; Witzens-Harig M; Böttcher S; Schmalenberg H; Marks R; Prange-Krex G; Kroschinsky F; Hauf E; Keller U; Koch K; Klapper W; Herold M; Scholz CW;
Ann Hematol; 2020 Dec; 99(12):2821-2829. PubMed ID: 32734548
[TBL] [Abstract][Full Text] [Related]
23. Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.
Jamois C; Gibiansky E; Gibiansky L; Buchheit V; Sahin D; Cartron G; Marcus R; Hiddemann W; Seymour JF; Strefford JC; Hargreaves CE; Meneses-Lorente G; Frey N; Fingerle-Rowson G
Br J Clin Pharmacol; 2019 Jul; 85(7):1495-1506. PubMed ID: 30866056
[TBL] [Abstract][Full Text] [Related]
24. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
Hornberger JC; Best JH
Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
26. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.
Wu JQ; Song YP; Su LP; Zhang MZ; Li W; Hu Y; Zhang XH; Gao YH; Niu ZX; Feng R; Wang W; Peng JW; Li XL; Ouyang XN; Wu CP; Zhang WJ; Zeng Y; Xiao Z; Liang YM; Zhuang YZ; Wang JS; Sun ZM; Bai H; Cui TJ; Feng JF
Chin Med J (Engl); 2018 Aug; 131(15):1767-1775. PubMed ID: 30058572
[TBL] [Abstract][Full Text] [Related]
27. Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction.
Hara T; Suzuki R; Ohno A; Yamakawa K; Yamagishi Y; Sugiyama Y; Sobajima T; Yamada R; Matsumoto R; Ikeda Y; Murayama M; Tsurumi H
Int J Hematol; 2020 Apr; 111(4):585-590. PubMed ID: 31848991
[TBL] [Abstract][Full Text] [Related]
28. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Vitolo U; Trněný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH
J Clin Oncol; 2017 Nov; 35(31):3529-3537. PubMed ID: 28796588
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma.
van Keep M; Gairy K; Seshagiri D; Thilakarathne P; Lee D
BMC Cancer; 2016 Aug; 16(1):598. PubMed ID: 27488675
[TBL] [Abstract][Full Text] [Related]
30. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Marcus R; Davies A; Ando K; Klapper W; Opat S; Owen C; Phillips E; Sangha R; Schlag R; Seymour JF; Townsend W; Trněný M; Wenger M; Fingerle-Rowson G; Rufibach K; Moore T; Herold M; Hiddemann W
N Engl J Med; 2017 Oct; 377(14):1331-1344. PubMed ID: 28976863
[TBL] [Abstract][Full Text] [Related]
31. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
Dewilde S; Woods B; Castaigne JG; Parker C; Dunlop W
J Med Econ; 2014 Feb; 17(2):111-24. PubMed ID: 24308372
[TBL] [Abstract][Full Text] [Related]
32. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.
Pott C; Jurinovic V; Trotman J; Kehden B; Unterhalt M; Herold M; Jagt RV; Janssens A; Kneba M; Mayer J; Young M; Schmidt C; Knapp A; Nielsen T; Brown H; Spielewoy N; Harbron C; Bottos A; Mundt K; Marcus R; Hiddemann W; Hoster E
J Clin Oncol; 2024 Feb; 42(5):550-561. PubMed ID: 38096461
[TBL] [Abstract][Full Text] [Related]
33. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
[TBL] [Abstract][Full Text] [Related]
34. Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma.
Soini EJ; Martikainen JA; Vihervaara V; Mustonen K; Nousiainen T
Clin Ther; 2012 Apr; 34(4):915-925.e2. PubMed ID: 22459623
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Chan TS; Khong PL; Kwong YL
Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
[No Abstract] [Full Text] [Related]
36. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma.
Hornberger J; Reyes C; Lubeck D; Valente N
Leuk Lymphoma; 2008 Feb; 49(2):227-36. PubMed ID: 18231908
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics.
Muneishi M; Nakamura A; Tachibana K; Suemitsu J; Hasebe S; Takeuchi K; Yakushijin Y
Int J Clin Oncol; 2018 Apr; 23(2):375-381. PubMed ID: 29063983
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study.
Blommestein HM; Issa DE; Pompen M; Ten Hoor G; Hogendoorn M; Joosten P; Zweegman S; Huijgens PC; Uyl-de Groot CA
Eur J Haematol; 2014; 92(5):398-406. PubMed ID: 24400940
[TBL] [Abstract][Full Text] [Related]
39. Watch-and-wait policy versus rituximab-combined chemotherapy in Japanese patients with intestinal follicular lymphoma.
Tari A; Kitadai Y; Mouri R; Takigawa H; Asaoku H; Mihara K; Takata K; Fujihara M; Yoshino T; Koga T; Fujimori S; Tanaka S; Chayama K
J Gastroenterol Hepatol; 2018 Aug; 33(8):1461-1468. PubMed ID: 29377265
[TBL] [Abstract][Full Text] [Related]
40. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
